SK C&C, Ilsung IS partner for AI-powered drug surveillance

[Courtesy of SK C&C]

South Korean digital solutions provider SK Inc. C&C has signed a partnership agreement with Ilsung IS Co. to develop an artificial intelligence (AI)-based service for generating adverse drug reaction reports based on its own AI solution Solur.

According to SK C&C on Monday, adverse drug reaction reports aim to gather diverse instances of undesirable effects or unintended illnesses occurring during pharmaceutical use, for dissemination to regulatory bodies domestically and internationally.

Solur efficiently organizes collected adverse reaction cases from various sources, generates reports using appropriate templates, and promptly shares them with relevant regulatory authorities.

SK C&C also aims to improve drug surveillance through a drug safety-focused AI system based on drug safety databases.

SK C&C highlights the role of generative AI in fostering a secure pharmaceutical environment, facilitating rapid analysis and dissemination of adverse drug reaction information to enable adaptable responses to market shifts.

The company also added that it plans to actively support Ilsung IS in adapting to pharmaceutical market dynamics by automating business processes through AI hyper-automation across various sectors.

SK C&C plans to expand its presence into the global pharmaceutical market, including Japan.